{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:30:48Z","timestamp":1794551448214,"version":"4.9.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Struct Mol Biol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41594-026-01839-y","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:07:43Z","timestamp":1782119263000},"page":"1341-1353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Structural basis of opioid receptor activation by PCP and ketamine"],"prefix":"10.1038","volume":"33","author":[{"given":"Qianru","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7404-897X","authenticated-orcid":false,"given":"Eve J.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-8956","authenticated-orcid":false,"given":"Nokomis","family":"Ramos-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9721-6195","authenticated-orcid":false,"given":"Vipin Ashok","family":"Rangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela V.","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalyn L.","family":"Critz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2445-8791","authenticated-orcid":false,"given":"Carl-Mikael","family":"Suomivuori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia L.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Whiddon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunpeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2610-680X","authenticated-orcid":false,"given":"Michael J.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin B.","family":"Land","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2931-3823","authenticated-orcid":false,"given":"Susruta","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1822-2384","authenticated-orcid":false,"given":"Jonathan F.","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2793","authenticated-orcid":false,"given":"Ron O.","family":"Dror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1620-3027","authenticated-orcid":false,"given":"Tao","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"1839_CR1","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1111\/bph.13222","volume":"172","author":"D Lodge","year":"2015","unstructured":"Lodge, D. & Mercier, M. S. Ketamine and phencyclidine: the good, the bad and the unexpected. Br. J. Pharmacol. 172, 4254\u20134276 (2015).","journal-title":"Br. J. Pharmacol."},{"key":"1839_CR2","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1021\/acschemneuro.8b00266","volume":"9","author":"JL Bertron","year":"2018","unstructured":"Bertron, J. L., Seto, M. & Lindsley, C. W. DARK classics in chemical neuroscience: phencyclidine (PCP). ACS Chem. Neurosci. 9, 2459\u20132474 (2018).","journal-title":"ACS Chem. Neurosci."},{"key":"1839_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00213-007-0808-x","volume":"193","author":"N Amitai","year":"2007","unstructured":"Amitai, N., Semenova, S. & Markou, A. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology (Berl.) 193, 521\u2013537 (2007).","journal-title":"Psychopharmacology (Berl.)"},{"key":"1839_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","volume":"20","author":"JD Jentsch","year":"1999","unstructured":"Jentsch, J. D. & Roth, R. H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20, 201\u2013225 (1999).","journal-title":"Neuropsychopharmacology"},{"key":"1839_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman, R. M. et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351\u2013354 (2000).","journal-title":"Biol. Psychiatry"},{"key":"1839_CR6","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1021\/acschemneuro.7b00074","volume":"8","author":"MW Tyler","year":"2017","unstructured":"Tyler, M. W., Yourish, H. B., Ionescu, D. F. & Haggarty, S. J. Classics in chemical neuroscience: ketamine. ACS Chem. Neurosci. 8, 1122\u20131134 (2017).","journal-title":"ACS Chem. Neurosci."},{"key":"1839_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1476-5381.1981.tb10440.x","volume":"73","author":"D Lawrence","year":"1981","unstructured":"Lawrence, D. & Livingston, A. Opiate-like analgesic activity in general anaesthetics. Br. J. Pharmacol. 73, 435\u2013442 (1981).","journal-title":"Br. J. Pharmacol."},{"key":"1839_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S2215-0366(19)30394-3","volume":"6","author":"EH Turner","year":"2019","unstructured":"Turner, E. H. Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatry 6, 977\u2013979 (2019).","journal-title":"Lancet Psychiatry"},{"key":"1839_CR9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.4103\/0970-9185.168149","volume":"32","author":"N Vadivelu","year":"2016","unstructured":"Vadivelu, N. et al. Role of ketamine for analgesia in adults and children. J. Anaesthesiol. Clin. Pharmacol. 32, 298\u2013306 (2016).","journal-title":"J. Anaesthesiol. Clin. Pharmacol."},{"key":"1839_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ajem.2023.05.026","volume":"70","author":"AN Beaudrie-Nunn","year":"2023","unstructured":"Beaudrie-Nunn, A. N. et al. Efficacy of analgesic and sub-dissociative dose ketamine for acute pain in the emergency department. Am. J. Emerg. Med. 70, 133\u2013139 (2023).","journal-title":"Am. J. Emerg. Med."},{"key":"1839_CR11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1476-5381.1983.tb11031.x","volume":"79","author":"NA Anis","year":"1983","unstructured":"Anis, N. A., Berry, S. C., Burton, N. R. & Lodge, D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br. J. Pharmacol. 79, 565\u2013575 (1983).","journal-title":"Br. J. Pharmacol."},{"key":"1839_CR12","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41586-023-06624-1","volume":"622","author":"S Ma","year":"2023","unstructured":"Ma, S. et al. Sustained antidepressant effect of ketamine through NMDAR trapping in the LHb. Nature 622, 802\u2013809 (2023).","journal-title":"Nature"},{"key":"1839_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/science.ado7010","volume":"385","author":"M Chen","year":"2024","unstructured":"Chen, M. et al. Brain region-specific action of ketamine as a rapid antidepressant. Science 385, eado7010 (2024).","journal-title":"Science"},{"key":"1839_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/BF00634458","volume":"99","author":"LJ Herberg","year":"1989","unstructured":"Herberg, L. J. & Rose, I. C. The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brain-stimulation reward. Psychopharmacology (Berl.) 99, 87\u201390 (1989).","journal-title":"Psychopharmacology (Berl.)"},{"key":"1839_CR15","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1007\/s00213-014-3451-3","volume":"231","author":"TM Hillhouse","year":"2014","unstructured":"Hillhouse, T. M., Porter, J. H. & Negus, S. S. Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats. Psychopharmacology (Berl.) 231, 2705\u20132716 (2014).","journal-title":"Psychopharmacology (Berl.)"},{"key":"1839_CR16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/j.1476-5381.1988.tb11726.x","volume":"95","author":"D Lodge","year":"1988","unstructured":"Lodge, D. et al. A comparison between the in vivo and in vitro activity of five potent and competitive NMDA antagonists. Br. J. Pharmacol. 95, 957\u2013965 (1988).","journal-title":"Br. J. Pharmacol."},{"key":"1839_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.1824728","volume":"251","author":"KA Trujillo","year":"1991","unstructured":"Trujillo, K. A. & Akil, H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251, 85\u201387 (1991).","journal-title":"Science"},{"key":"1839_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1600-0773.1995.tb01041.x","volume":"77","author":"O Hustveit","year":"1995","unstructured":"Hustveit, O., Maurset, A. & Oye, I. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol. Toxicol. 77, 355\u2013359 (1995).","journal-title":"Pharmacol. Toxicol."},{"key":"1839_CR19","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","volume":"26","author":"J Bonaventura","year":"2021","unstructured":"Bonaventura, J. et al. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol. Psychiatry 26, 6704\u20136722 (2021).","journal-title":"Mol. Psychiatry"},{"key":"1839_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1460-9568.1996.tb01228.x","volume":"8","author":"CG Parsons","year":"1996","unstructured":"Parsons, C. G., Panchenko, V. A., Pinchenko, V. O., Tsyndrenko, A. Y. & Krishtal, O. A. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur. J. Neurosci. 8, 446\u2013454 (1996).","journal-title":"Eur. J. Neurosci."},{"key":"1839_CR21","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"NR Williams","year":"2018","unstructured":"Williams, N. R. et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am. J. Psychiatry 175, 1205\u20131215 (2018).","journal-title":"Am. J. Psychiatry"},{"key":"1839_CR22","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","volume":"24","author":"NR Williams","year":"2019","unstructured":"Williams, N. R. et al. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol. Psychiatry 24, 1779\u20131786 (2019).","journal-title":"Mol. Psychiatry"},{"key":"1839_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1176\/appi.ajp.2018.18111231","volume":"176","author":"R Amiaz","year":"2019","unstructured":"Amiaz, R. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism: is it a ketamine-specific effect? Am. J. Psychiatry 176, 250\u2013251 (2019).","journal-title":"Am. J. Psychiatry"},{"key":"1839_CR24","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1038\/npp.2017.60","volume":"42","author":"BA Samuels","year":"2017","unstructured":"Samuels, B. A. et al. The behavioral effects of the antidepressant tianeptine require the mu-opioid receptor. Neuropsychopharmacology 42, 2052\u20132063 (2017).","journal-title":"Neuropsychopharmacology"},{"key":"1839_CR25","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.biopsych.2022.12.019","volume":"93","author":"MR Levinstein","year":"2023","unstructured":"Levinstein, M. R. et al. Mu opioid receptor activation mediates (S)-ketamine reinforcement in rats: implications for abuse liability. Biol Psychiatry 93, 1118\u20131126 (2023).","journal-title":"Biol Psychiatry"},{"key":"1839_CR26","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1124\/molpharm.124.000947","volume":"106","author":"I Gomes","year":"2024","unstructured":"Gomes, I., Gupta, A., Margolis, E. B., Fricker, L. D. & Devi, L. A. Ketamine and major ketamine metabolites function as allosteric modulators of opioid receptors. Mol. Pharmacol. 106, 240\u2013252 (2024).","journal-title":"Mol. Pharmacol."},{"key":"1839_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0091-3057(02)00961-9","volume":"74","author":"AK Baker","year":"2002","unstructured":"Baker, A. K., Hoffmann, V. L. & Meert, T. F. Dextromethorphan and ketamine potentiate the antinociceptive effects of \u03bc- but not \u03b4- or \u03ba-opioid agonists in a mouse model of acute pain. Pharmacol. Biochem. Behav. 74, 73\u201386 (2002).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"1839_CR28","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1172\/JCI32420","volume":"117","author":"C Muscoli","year":"2007","unstructured":"Muscoli, C. et al. Therapeutic manipulation of peroxynitrite attenuates the development of opiate-induced antinociceptive tolerance in mice. J. Clin. Invest. 117, 3530\u20133539 (2007).","journal-title":"J. Clin. Invest."},{"key":"1839_CR29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/00000542-199901000-00023","volume":"90","author":"K Hirota","year":"1999","unstructured":"Hirota, K. et al. Stereoselective interaction of ketamine with recombinant \u03bc, \u03ba, and \u03b4 opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology 90, 174\u2013182 (1999).","journal-title":"Anesthesiology"},{"key":"1839_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0379-0738(00)00180-8","volume":"112","author":"C Giroud","year":"2000","unstructured":"Giroud, C. et al. Salvia divinorum: an hallucinogenic mint which might become a new recreational drug in Switzerland. Forensic Sci. Int. 112, 143\u2013150 (2000).","journal-title":"Forensic Sci. Int."},{"key":"1839_CR31","doi-asserted-by":"publisher","first-page":"11934","DOI":"10.1073\/pnas.182234399","volume":"99","author":"BL Roth","year":"2002","unstructured":"Roth, B. L. et al. Salvinorin A: a potent naturally occurring nonnitrogenous \u03ba opioid selective agonist. Proc Natl Acad Sci USA 99, 11934\u201311939 (2002).","journal-title":"Proc Natl Acad Sci USA"},{"key":"1839_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00213-010-1834-7","volume":"210","author":"CL Nemeth","year":"2010","unstructured":"Nemeth, C. L. et al. Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. Psychopharmacology (Berl.) 210, 263\u2013274 (2010).","journal-title":"Psychopharmacology (Berl.)"},{"key":"1839_CR33","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1016\/j.cell.2022.09.041","volume":"185","author":"Y Zhuang","year":"2022","unstructured":"Zhuang, Y. et al. Molecular recognition of morphine and fentanyl by the human \u03bc-opioid receptor. Cell 185, 4361\u20134375 (2022).","journal-title":"Cell"},{"key":"1839_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059334","volume":"8","author":"BL Roth","year":"2013","unstructured":"Roth, B. L. et al. The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS ONE 8, e59334 (2013).","journal-title":"PLoS ONE"},{"key":"1839_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-023-06030-7","volume":"617","author":"J Han","year":"2023","unstructured":"Han, J. et al. Ligand and G-protein selectivity in the \u03ba-opioid receptor. Nature 617, 417\u2013425 (2023).","journal-title":"Nature"},{"key":"1839_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cell.2022.12.026","volume":"186","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Structures of the entire human opioid receptor family. Cell 186, 413\u2013427 e417 (2023).","journal-title":"Cell"},{"key":"1839_CR37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature14886","volume":"524","author":"WJ Huang","year":"2015","unstructured":"Huang, W. J. et al. Structural insights into \u03bc-opioid receptor activation. Nature 524, 315\u2013321 (2015).","journal-title":"Nature"},{"key":"1839_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cell.2017.12.011","volume":"172","author":"T Che","year":"2018","unstructured":"Che, T. et al. Structure of the nanobody-stabilized active state of the kappa opioid receptor. Cell 172, 55\u201367 (2018).","journal-title":"Cell"},{"key":"1839_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax9115","volume":"5","author":"T Claff","year":"2019","unstructured":"Claff, T. et al. Elucidating the active \u03b4-opioid receptor crystal structure with peptide and small-molecule agonists. Sci. Adv. 5, eaax9115 (2019).","journal-title":"Sci. Adv."},{"key":"1839_CR40","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/jat\/21.5.356","volume":"21","author":"Y Nakahara","year":"1997","unstructured":"Nakahara, Y. et al. Hair analysis for drugs of abuse. XVII. Simultaneous detection of PCP, PCHP, and PCPdiol in human hair for confirmation of PCP use. J. Anal. Toxicol. 21, 356\u2013362 (1997).","journal-title":"J. Anal. Toxicol."},{"key":"1839_CR41","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/jm00141a006","volume":"24","author":"FI Carroll","year":"1981","unstructured":"Carroll, F. I. et al. Phencyclidine metabolism: resolution, structure, and biological activity of the isomers of the hydroxy metabolite, 4-phenyl-4-(1-piperidinyl)cyclohexanol. J. Med. Chem. 24, 1047\u20131051 (1981).","journal-title":"J. Med. Chem."},{"key":"1839_CR42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0024-3205(97)01153-3","volume":"62","author":"T Sakamoto","year":"1998","unstructured":"Sakamoto, T., Tanaka, A. & Nakahara, Y. Incorporation of phencyclidine and its hydroxylated metabolites into hair. Life Sci. 62, 561\u2013570 (1998).","journal-title":"Life Sci."},{"key":"1839_CR43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14728222.2019.1586882","volume":"23","author":"AT Ehrlich","year":"2019","unstructured":"Ehrlich, A. T., Kieffer, B. L. & Darcq, E. Current strategies toward safer mu opioid receptor drugs for pain management. Expert Opin. Ther. Targets 23, 315\u2013326 (2019).","journal-title":"Expert Opin. Ther. Targets"},{"key":"1839_CR44","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature14886","volume":"524","author":"W Huang","year":"2015","unstructured":"Huang, W. et al. Structural insights into \u03bc-opioid receptor activation. Nature 524, 315\u2013321 (2015).","journal-title":"Nature"},{"key":"1839_CR45","doi-asserted-by":"publisher","first-page":"R121","DOI":"10.1016\/S1359-0278(96)00056-9","volume":"1","author":"A Horovitz","year":"1996","unstructured":"Horovitz, A. Double-mutant cycles: a powerful tool for analyzing protein structure and function. Fold. Des. 1, R121\u2013R126 (1996).","journal-title":"Fold. Des."},{"key":"1839_CR46","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.1074\/jbc.M113.502021","volume":"289","author":"X Pedragosa-Badia","year":"2014","unstructured":"Pedragosa-Badia, X. et al. Pancreatic polypeptide is recognized by two hydrophobic domains of the human Y4 receptor binding pocket. J. Biol. Chem. 289, 5846\u20135859 (2014).","journal-title":"J. Biol. Chem."},{"key":"1839_CR47","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.str.2020.04.018","volume":"28","author":"MJ Robertson","year":"2020","unstructured":"Robertson, M. J., van Zundert, G. C. P., Borrelli, K. & Skiniotis, G. GemSpot: a pipeline for robust modeling of ligands into cryo-EM maps. Structure 28, 707\u2013716 (2020).","journal-title":"Structure"},{"key":"1839_CR48","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41586-021-03769-9","volume":"596","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Structural basis of ketamine action on human NMDA receptors. Nature 596, 301\u2013305 (2021).","journal-title":"Nature"},{"key":"1839_CR49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/bph.15680","volume":"179","author":"K Stefkova-Mazochova","year":"2022","unstructured":"Stefkova-Mazochova, K. et al. Pharmacokinetic, pharmacodynamic, and behavioural studies of deschloroketamine in Wistar rats. Br. J. Pharmacol. 179, 65\u201383 (2022).","journal-title":"Br. J. Pharmacol."},{"key":"1839_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.972798","volume":"15","author":"H Du","year":"2022","unstructured":"Du, H. et al. A comparison of reinforcing effectiveness and drug-seeking reinstatement of 2-fluorodeschloroketamine and ketamine in self-administered rats. Front. Mol. Neurosci. 15, 972798 (2022).","journal-title":"Front. Mol. Neurosci."},{"key":"1839_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2022.173333","volume":"213","author":"JM Kim","year":"2022","unstructured":"Kim, J. M. et al. Rewarding and reinforcing effects of two dissociative-based new psychoactive substances, deschloroketamine and diphenidine, in mice. Pharmacol. Biochem. Behav. 213, 173333 (2022).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"1839_CR52","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.pbb.2008.05.019","volume":"90","author":"JR Holtman Jr","year":"2008","unstructured":"Holtman, J. R. Jr, Crooks, P. A., Johnson-Hardy, J. & Wala, E. P. Interaction between morphine and norketamine enantiomers in rodent models of nociception. Pharmacol. Biochem. Behav. 90, 769\u2013777 (2008).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"1839_CR53","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.pbb.2008.05.011","volume":"90","author":"JR Holtman Jr","year":"2008","unstructured":"Holtman, J. R. Jr et al. Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol. Biochem. Behav. 90, 676\u2013685 (2008).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"1839_CR54","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tips.2007.06.003","volume":"28","author":"BK Kobilka","year":"2007","unstructured":"Kobilka, B. K. & Deupi, X. Conformational complexity of G-protein-coupled receptors. Trends Pharmacol. Sci. 28, 397\u2013406 (2007).","journal-title":"Trends Pharmacol. Sci."},{"key":"1839_CR55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1021\/acsptsci.8b00017","volume":"1","author":"YL Liang","year":"2018","unstructured":"Liang, Y. L. et al. Dominant negative G proteins enhance formation and purification of agonist\u2013GPCR\u2013G protein complexes for structure determination. ACS Pharmacol. Transl. Sci. 1, 12\u201320 (2018).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"1839_CR56","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/s41589-024-01812-0","volume":"21","author":"AS Tyson","year":"2025","unstructured":"Tyson, A. S. et al. Molecular mechanisms of inverse agonism via \u03ba-opioid receptor-G protein complexes. Nat. Chem. Biol. 21, 1046\u20131057 (2025).","journal-title":"Nat. Chem. Biol."},{"key":"1839_CR57","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41586-020-2019-0","volume":"579","author":"X Lin","year":"2020","unstructured":"Lin, X. et al. Structural basis of ligand recognition and self-activation of orphan GPR52. Nature 579, 152\u2013157 (2020).","journal-title":"Nature"},{"key":"1839_CR58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41589-023-01389-0","volume":"20","author":"Q Guo","year":"2024","unstructured":"Guo, Q. et al. A method for structure determination of GPCRs in various states. Nat. Chem. Biol. 20, 74\u201382 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"1839_CR59","first-page":"293","volume":"25","author":"X Deupi","year":"2010","unstructured":"Deupi, X. & Kobilka, B. K. Energy landscapes as a tool to integrate GPCR structure, dynamics, and function. Physiology (Bethesda) 25, 293\u2013303 (2010).","journal-title":"Physiology (Bethesda)"},{"key":"1839_CR60","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1146\/annurev-biochem-060614-033910","volume":"87","author":"WI Weis","year":"2018","unstructured":"Weis, W. I. & Kobilka, B. K. The molecular basis of G protein-coupled receptor activation. Annu. Rev. Biochem. 87, 897\u2013919 (2018).","journal-title":"Annu. Rev. Biochem."},{"key":"1839_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1007394","volume":"16","author":"PW de Waal","year":"2020","unstructured":"de Waal, P. W. et al. Molecular mechanisms of fentanyl mediated \u03b2-arrestin biased signaling. PLoS Comput. Biol. 16, e1007394 (2020).","journal-title":"PLoS Comput. Biol."},{"key":"1839_CR62","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41594-022-00772-0","volume":"29","author":"TH Chou","year":"2022","unstructured":"Chou, T. H. et al. Structural insights into binding of therapeutic channel blockers in NMDA receptors. Nat. Struct. Mol. Biol. 29, 507\u2013518 (2022).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1839_CR63","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41589-022-01208-y","volume":"19","author":"Q Qu","year":"2023","unstructured":"Qu, Q. et al. Insights into distinct signaling profiles of the \u03bcOR activated by diverse agonists. Nat. Chem. Biol. 19, 423\u2013430 (2023).","journal-title":"Nat. Chem. Biol."},{"key":"1839_CR64","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1016\/j.cell.2023.10.029","volume":"186","author":"T Che","year":"2023","unstructured":"Che, T. & Roth, B. L. Molecular basis of opioid receptor signaling. Cell 186, 5203\u20135219 (2023).","journal-title":"Cell"},{"key":"1839_CR65","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.brainres.2014.03.026","volume":"1562","author":"F Pacheco Dda","year":"2014","unstructured":"Pacheco Dda, F., Romero, T. R. & Duarte, I. D. Central antinociception induced by ketamine is mediated by endogenous opioids and \u03bc- and \u03b4-opioid receptors. Brain Res. 1562, 69\u201375 (2014).","journal-title":"Brain Res."},{"key":"1839_CR66","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41386-023-01652-x","volume":"49","author":"MR Levinstein","year":"2024","unstructured":"Levinstein, M. R. & Michaelides, M. Exploring the role of mu opioid receptors in the therapeutic potential and abuse liability of (S)-ketamine. Neuropsychopharmacology 49, 315\u2013316 (2024).","journal-title":"Neuropsychopharmacology"},{"key":"1839_CR67","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cell.2009.09.028","volume":"139","author":"AI Basbaum","year":"2009","unstructured":"Basbaum, A. I., Bautista, D. M., Scherrer, G. & Julius, D. Cellular and molecular mechanisms of pain. Cell 139, 267\u2013284 (2009).","journal-title":"Cell"},{"key":"1839_CR68","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.conb.2004.05.005","volume":"14","author":"C Contet","year":"2004","unstructured":"Contet, C., Kieffer, B. L. & Befort, K. Mu opioid receptor: a gateway to drug addiction. Curr. Opin. Neurobiol. 14, 370\u2013378 (2004).","journal-title":"Curr. Opin. Neurobiol."},{"key":"1839_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104800","volume":"140","author":"LA Jelen","year":"2022","unstructured":"Jelen, L. A., Stone, J. M., Young, A. H. & Mehta, M. A. The opioid system in depression. Neurosci. Biobehav. Rev. 140, 104800 (2022).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"1839_CR70","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1126\/science.3016896","volume":"233","author":"A Pfeiffer","year":"1986","unstructured":"Pfeiffer, A., Brantl, V., Herz, A. & Emrich, H. M. Psychotomimesis mediated by \u03ba opiate receptors. Science 233, 774\u2013776 (1986).","journal-title":"Science"},{"key":"1839_CR71","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0014-2999(89)90754-1","volume":"167","author":"MD Tricklebank","year":"1989","unstructured":"Tricklebank, M. D., Singh, L., Oles, R. J., Preston, C. & Iversen, S. D. The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur. J. Pharmacol. 167, 127\u2013135 (1989).","journal-title":"Eur. J. Pharmacol."},{"key":"1839_CR72","doi-asserted-by":"publisher","first-page":"19168","DOI":"10.1073\/pnas.0910705106","volume":"106","author":"BB Land","year":"2009","unstructured":"Land, B. B. et al. Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc. Natl Acad. Sci. USA 106, 19168\u201319173 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1839_CR73","doi-asserted-by":"publisher","first-page":"8031","DOI":"10.1523\/JNEUROSCI.0653-18.2018","volume":"38","author":"AD Abraham","year":"2018","unstructured":"Abraham, A. D. et al. Estrogen regulation of GRK2 inactivates kappa opioid receptor signaling mediating analgesia, but not aversion. J. Neurosci. 38, 8031\u20138043 (2018).","journal-title":"J. Neurosci."},{"key":"1839_CR74","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0014-2999(91)90101-U","volume":"194","author":"T Crisp","year":"1991","unstructured":"Crisp, T., Perrotti, J. M., Smith, D. L., Stafinsky, J. L. & Smith, D. J. The local monoaminergic dependency of spinal ketamine. Eur. J. Pharmacol. 194, 167\u2013172 (1991).","journal-title":"Eur. J. Pharmacol."},{"key":"1839_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-02796-0","volume":"14","author":"C Jiang","year":"2024","unstructured":"Jiang, C., DiLeone, R. J., Pittenger, C. & Duman, R. S. The endogenous opioid system in the medial prefrontal cortex mediates ketamine\u2019s antidepressant-like actions. Transl. Psychiatry 14, 90 (2024).","journal-title":"Transl. Psychiatry"},{"key":"1839_CR76","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1016\/j.cell.2026.04.006","volume":"189","author":"H Munguba","year":"2026","unstructured":"Munguba, H. et al. Mechanism-guided identification of antidepressant G protein-coupled receptor drug targets. Cell 189, 2612\u20132632 (2026).","journal-title":"Cell"},{"key":"1839_CR77","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.biopsych.2025.07.004","volume":"99","author":"CB Langreck","year":"2026","unstructured":"Langreck, C. B. et al. Mu opioid receptor activation is required for NMDA receptor antagonist effects on stress-induced maladaptive behavior. Biol Psychiatry 99, 299\u2013310 (2026).","journal-title":"Biol Psychiatry"},{"key":"1839_CR78","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","volume":"76","author":"G Yoon","year":"2019","unstructured":"Yoon, G., Petrakis, I. L. & Krystal, J. H. Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiatry 76, 337\u2013338 (2019).","journal-title":"JAMA Psychiatry"},{"key":"1839_CR79","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1097\/00000542-199906000-00007","volume":"90","author":"S Mikkelsen","year":"1999","unstructured":"Mikkelsen, S., Ilkjaer, S., Brennum, J., Borgbjerg, F. M. & Dahl, J. B. The effect of naloxone on ketamine-induced effects on hyperalgesia and ketamine-induced side effects in humans. Anesthesiology 90, 1539\u20131545 (1999).","journal-title":"Anesthesiology"},{"key":"1839_CR80","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.biopsych.2012.03.004","volume":"72","author":"CA Zarate Jr.","year":"2012","unstructured":"Zarate, C. A. Jr. et al. Relationship of ketamine\u2019s plasma metabolites with response, diagnosis, and side effects in major depression. Biol. Psychiatry 72, 331\u2013338 (2012).","journal-title":"Biol. Psychiatry"},{"key":"1839_CR81","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos, P. et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol. Rev. 70, 621\u2013660 (2018).","journal-title":"Pharmacol. Rev."},{"key":"1839_CR82","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1093\/bja\/51.12.1167","volume":"51","author":"J Idvall","year":"1979","unstructured":"Idvall, J., Ahlgren, I., Aronsen, K. R. & Stenberg, P. Ketamine infusions: pharmacokinetics and clinical effects. Br. J. Anaesth. 51, 1167\u20131173 (1979).","journal-title":"Br. J. Anaesth."},{"key":"1839_CR83","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1213\/00000539-198202000-00004","volume":"61","author":"EF Domino","year":"1982","unstructured":"Domino, E. F. et al. Plasma levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass fragmentographic assay. Anesth. Analg. 61, 87\u201392 (1982).","journal-title":"Anesth. Analg."},{"key":"1839_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00082","volume":"6","author":"FM Heydenreich","year":"2015","unstructured":"Heydenreich, F. M., Vuckovic, Z., Matkovic, M. & Veprintsev, D. B. Stabilization of G protein-coupled receptors by point mutations. Front. Pharmacol. 6, 82 (2015).","journal-title":"Front. Pharmacol."},{"key":"1839_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06002-w","volume":"9","author":"S Maeda","year":"2018","unstructured":"Maeda, S. et al. Development of an antibody fragment that stabilizes GPCR\/G-protein complexes. Nat. Commun. 9, 3712 (2018).","journal-title":"Nat. Commun."},{"key":"1839_CR86","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"1839_CR87","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41592-020-00990-8","volume":"17","author":"A Punjani","year":"2020","unstructured":"Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat. Methods 17, 1214\u20131221 (2020).","journal-title":"Nat. Methods"},{"key":"1839_CR88","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pro.3235","volume":"27","author":"TD Goddard","year":"2018","unstructured":"Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14\u201325 (2018).","journal-title":"Protein Sci."},{"key":"1839_CR89","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"1839_CR90","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"1839_CR91","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12\u201321 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"1839_CR92","doi-asserted-by":"publisher","first-page":"10576","DOI":"10.1074\/jbc.M609695200","volume":"282","author":"LI Jiang","year":"2007","unstructured":"Jiang, L. I. et al. Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate\/G13 pathway. J. Biol. Chem. 282, 10576\u201310584 (2007).","journal-title":"J. Biol. Chem."},{"key":"1839_CR93","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/bioinformatics\/btk023","volume":"22","author":"MA Lomize","year":"2006","unstructured":"Lomize, M. A., Lomize, A. L., Pogozheva, I. D. & Mosberg, H. I. OPM: Orientations of Proteins in Membranes database. Bioinformatics 22, 623\u2013625 (2006).","journal-title":"Bioinformatics"},{"key":"1839_CR94","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0022-2836(02)00470-9","volume":"320","author":"MP Jacobson","year":"2002","unstructured":"Jacobson, M. P., Friesner, R. A., Xiang, Z. & Honig, B. On the role of the crystal environment in determining protein side-chain conformations. J. Mol. Biol. 320, 597\u2013608 (2002).","journal-title":"J. Mol. Biol."},{"key":"1839_CR95","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1074\/jbc.275.5.3121","volume":"275","author":"P Ghanouni","year":"2000","unstructured":"Ghanouni, P. et al. The effect of pH on \u03b22 adrenoceptor function: evidence for protonation-dependent activation. J. Biol. Chem. 275, 3121\u20133127 (2000).","journal-title":"J. Biol. Chem."},{"key":"1839_CR96","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1021\/bi5008723","volume":"53","author":"A Ranganathan","year":"2014","unstructured":"Ranganathan, A., Dror, R. O. & Carlsson, J. Insights into the role of Asp792.50 in \u03b22 adrenergic receptor activation from molecular dynamics simulations. Biochemistry 53, 7283\u20137296 (2014).","journal-title":"Biochemistry"},{"key":"1839_CR97","doi-asserted-by":"publisher","unstructured":"Betz, R. Dabble. Zenodo https:\/\/doi.org\/10.5281\/zenodo.836914 (2017).","DOI":"10.5281\/zenodo.836914"},{"key":"1839_CR98","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nmeth.4067","volume":"14","author":"J Huang","year":"2017","unstructured":"Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat. Methods 14, 71\u201373 (2017).","journal-title":"Nat. Methods"},{"key":"1839_CR99","doi-asserted-by":"publisher","first-page":"7830","DOI":"10.1021\/jp101759q","volume":"114","author":"JB Klauda","year":"2010","unstructured":"Klauda, J. B. et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. J. Phys. Chem. B 114, 7830\u20137843 (2010).","journal-title":"J. Phys. Chem. B"},{"key":"1839_CR100","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1021\/acs.jcim.8b00462","volume":"58","author":"TS Lee","year":"2018","unstructured":"Lee, T. S. et al. GPU-accelerated molecular dynamics and free energy methods in Amber18: performance enhancements and new features. J. Chem. Inf. Model. 58, 2043\u20132050 (2018).","journal-title":"J. Chem. Inf. Model."},{"key":"1839_CR101","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","volume":"23","author":"JP Ryckaert","year":"1977","unstructured":"Ryckaert, J. P., Ciccotti, G. & Berendsen, H. J. C. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 23, 327\u2013341 (1977).","journal-title":"J. Comput. Phys."},{"key":"1839_CR102","doi-asserted-by":"publisher","unstructured":"Fine, E., Suomivuori, C.-M. & Dror, R. MD data for \u2018Cryo-EM structures of ketamine bound to opioid receptors\u2019. Zenodo https:\/\/doi.org\/10.5281\/zenodo.18987592 (2026).","DOI":"10.5281\/zenodo.18987592"}],"container-title":["Nature Structural & Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41594-026-01839-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41594-026-01839-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41594-026-01839-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:02:38Z","timestamp":1789077758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41594-026-01839-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":102,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1839"],"URL":"https:\/\/doi.org\/10.1038\/s41594-026-01839-y","relation":{},"ISSN":["1545-9993","1545-9985"],"issn-type":[{"value":"1545-9993","type":"print"},{"value":"1545-9985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.M. is a co-founder of Sparian biosciences. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}